Nanjing Leads Biolabs Co.,Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS12
PHASE 3 / 2-31
RECRUITING11
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO43%
Delay Index: of 7 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +1.2 months). See all sponsors →
Open Nanjing Leads Biolabs Co.,Ltd on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| LBL-024 for Injection NCT05170958 |
P1/2 | Recruiting | Advanced Solid Tumor | 396 | 2026-12 (+29 mo) |
| LBL-024 for Injection NCT06783647 |
P2 | Recruiting | Advanced Solid Tumour | 250 | 2026-12-24 |
| LBL-024 for Injection NCT06157827 |
P1/2 | Recruiting | Advanced Neuroendocrine Carcinoma | 178 | 2026-12-28 (+1 mo) |
| LBL-024 for Injection NCT07099430 |
P1/2 | Recruiting | Advanced Melanoma | 280 | 2027-10-30 |
| LBL-024 for Injection NCT07042802 |
P1/2 | Recruiting | Ovarian Cancer | 180 | 2027-12-25 |
| LBL-024 for Injection NCT07111546 |
P2 | Recruiting | Advanced Solid Tumour | 140 | 2027-12-26 (+12 mo) |
| LBL-024 for Injection NCT07281976 |
P1/2 | Recruiting | Triple Negative Breast Cancer | 220 | 2027-12-31 |
| LBL-024 for Injection NCT07390383 |
P2 | Recruiting | Advanced Solid Tumour | 110 | 2028-05-30 |
| LBL-024 for Injection NCT07331155 |
P2 | Recruiting | Advanced Solid Tumour | 110 | 2028-12-26 |
| LBL-034 for Injection NCT06049290 |
P1/2 | Recruiting | Relapsed/Refractory Multiple Myeloma | 342 | 2029-09-20 (+35 mo) |
| LBL-024 for Injection NCT07791758 |
P1/2 | Recruiting | Metastatic Colorectal Carcinoma | 369 | 2030-09-04 |
| LBL-024 for Injection NCT07720193 |
P3 | Not yet recruiting | Advanced Extrapulmonary Neuroendocrine Carcinoma | 280 | 2030-12-22 |